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OBJECTIVE—Patients with diabetic erectile dysfunction often
have severe endothelial dysfunction and respond poorly to oral
phosphodiesterase-5 inhibitors. We examined the effectiveness of
the potent angiopoietin-1 (Ang1) variant, cartilage oligomeric
matrix protein (COMP)-Ang1, in promoting cavernous endothelial
regeneration and restoring erectile function in diabetic animals.
RESEARCH DESIGN AND METHODS—Four groups of mice
were used: controls; streptozotocin (STZ)-induced diabetic mice;
STZ-induced diabetic mice treated with repeated intracavernous
injections of PBS; and STZ-induced diabetic mice treated with
COMP-Ang1 protein (days 23 and 0). Two and 4 weeks after
treatment, we measured erectile function by electrical stimula-
tion of the cavernous nerve. The penis was harvested for histologic
examinations, Western blot analysis, and cGMP quantiﬁcation. We
also performed a vascular permeability test.
RESULTS—Local delivery of the COMP-Ang1 protein signiﬁ-
cantly increased cavernous endothelial proliferation, endothelial
nitric oxide (NO) synthase (NOS) phosphorylation, and cGMP
expression compared with that in the untreated or PBS-treated
STZ-induced diabetic group. The changes in the group that
received COMP-Ang1 restored erectile function up to 4 weeks
after treatment. Endothelial protective effects, such as marked
decreases in the expression of p47
phox and inducible NOS, in the
generation of superoxide anion and nitrotyrosine, and in the num-
ber of apoptotic cells in the corpus cavernosum tissue, were
noted in COMP-Ang1–treated STZ-induced diabetic mice. An
intracavernous injection of COMP-Ang1 completely restored en-
dothelial cell-cell junction proteins and decreased cavernous
endothelial permeability. COMP-Ang1–induced promotion of cav-
ernous angiogenesis and erectile function was abolished by the
NOS inhibitor, N-nitro-L-arginine methyl ester, but not by the
NADPH oxidase inhibitor, apocynin.
CONCLUSIONS—These ﬁndings support the concept of cav-
ernous endothelial regeneration by use of the recombinant Ang1
protein as a curative therapy for diabetic erectile dysfunction.
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E
rectile dysfunction affects up to 75% of all men
with diabetes and occurs earlier in such patients
than in the general population (1,2). The Massa-
chusetts Male Aging Study revealed that erectile
dysfunction is three times as prevalent in diabetic men as
in men without diabetes (3). Moreover, men with diabetic
erectile dysfunction tend to respond less positively to the
currently available oral phosphodiesterase-5 (PDE5) in-
hibitors than do nondiabetic men (4–6). The reduced re-
sponsiveness to PDE5 inhibitors in patients with diabetes
may be related to the severity of endothelial dysfunction
(7). Because the effects of PDE5 inhibitors rely on en-
dogenous nitric oxide (NO) formation, PDE5 inhibitors
may fail to increase the level of cyclic guanosine mono-
phosphate (cGMP) above the necessary threshold if the
bioavailable NO is insufﬁcient as a result of severe endo-
thelial dysfunction. Furthermore, PDE5 inhibitors must
be used on demand, thus limiting the spontaneity of the
sexual act. The use of PDE5 inhibitors is absolutely con-
traindicated in men who take nitrate compounds because
of the risk of extreme hypotension or even death (8).
Therefore, new therapeutic strategies are needed.
Augmented generation of reactive oxygen species (ROS)
is one of the major causes of decreased NO bioavailability
in diabetes (9–12). We recently reported in streptozotocin
(STZ)-induced type 1 diabetic mice that increased super-
oxide anion production and peroxynitrite formation in the
corpus cavernosum tissue play an important role in the
diabetes-induced functional and structural impairments in
the cavernous endothelium, such as the decrease in en-
dothelial NO synthase (eNOS) enzyme activity, endothelial
cell apoptosis, and subsequent loss of endothelial cell
content (12). Therefore, restoring NO bioavailability by
inhibiting ROS-mediated endothelial cell damage, regen-
erating cavernous endothelial cells, or both may serve as
promising therapeutic strategies for treating patients with
diabetic erectile dysfunction.
Various antioxidants have been shown to improve en-
dothelial function and erectile ability in animal models
of diabetic erectile dysfunction (10,13,14). Adenovirus-
mediated gene transfer of extracellular superoxide dis-
mutase into the corpus cavernosum tissue was shown to
reduce superoxide anion levels and raise cavernous cGMP
levels, which resulted in partial recovery of erectile func-
tion in STZ-induced diabetic rats 2 days after transfection
(14). Despite encouraging results in preclinical studies,
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ORIGINAL ARTICLEhowever, no antioxidants have so far been approved for
the treatment of patients with erectile dysfunction. A pos-
sible reason is that antioxidant therapy may not be ef-
fective if structural damage to cavernous endothelial cells
has already progressed. In this regard, regeneration of
damaged endothelial cells using angiogenic factors is
a more logical approach to treating erectile dysfunction
than is the prevention of endothelial cell damage with
antioxidants.
Local delivery of the vascular endothelial growth factor-
A (VEGF-A) gene or protein into the penis has been shown
to induce partial or complete recovery of erectile function
in STZ-induced type 1 diabetic rats (15–17). However,
these studies did not demonstrate whether VEGF-A ther-
apy induces endothelial regeneration. Furthermore, VEGF-
A often leads to the formation of disorganized vessels that
are leaky, hyperpermeable, and inﬂamed in experimental
systems (18,19), thus greatly compromising the therapeutic
utility of VEGF-A. In comparison, angiopoietin-1 (Ang1),
the ligand of the Tie2 receptor tyrosine kinase, is a speciﬁc
growth factor that functions to generate a nonleaky, sta-
ble, and functional vasculature (19–22). Transgenic over-
expression or gene transfer of Ang1 not only enhances
vessel formation but also protects the adult vasculature
against vascular leakage (19,23–25). Thus, Ang1 has po-
tential therapeutic applications in angiogenesis and the
prevention of vascular leakage. However, our previous
study (26) revealed that a single intracavernous delivery of
the adenovirus-mediated Ang1 gene failed to induce an
angiogenic response in the penis of a hypercholesterol-
emic rat. Recently, Cho et al. (27) developed a soluble and
potent Ang1 variant, cartilage oligomeric matrix protein
(COMP)-Ang1, that is more potent than native Ang1 in
phosphorylating Tie2 in primary cultured endothelial cells.
COMP-Ang1 stimulates angiogenesis with nonleaky neo-
vessel formation in the mouse corneal micropocket assay,
whereas VEGF-A stimulates angiogenesis with leaky neo-
vessel formation (27). One mechanism for inducing non-
leaky and healthy angiogenesis is the speciﬁc activation
of Tie2 in endothelial cell-cell or cell-matrix contacts by
COMP-Ang1 (28,29).
In the current study, we determined the effectiveness
of COMP-Ang1 in promoting cavernous endothelial regen-
eration and restoring erectile function in a mouse model
of diabetic erectile dysfunction. In addition, because in-
creased vascular permeability by loss of endothelial cell-
cell junction proteins is an important pathophysiological
mechanism involved in diabetic retinopathy (30–33), we
investigated whether COMP-Ang1 induces nonleaky an-
giogenesis in the penis by restoring endothelial cell-cell
junction proteins.
RESEARCH DESIGN AND METHODS
Generation of COMP-Ang1 adenovirus and COMP-Ang1 recombinant
protein. Recombinant adenovirus-expressing FLAG-tagged COMP-Ang1 or
bacterial b-gal was constructed and COMP-Ang1 recombinant protein was
prepared as previously described (22).
Animals and treatments. Eight-week-old C57BL/6J mice were used in this
study. The experiments were approved by the institutional animal care and use
subcommittee of our university. Diabetes was induced by intraperitoneal
injections of multiple low doses of STZ (50 mg/kg body wt in 0.1 mol/L citrate
buffer, pH 4.5) consecutively for 5 days, as previously described (12). Eight
weeks after diabetes was induced, the animals were anesthetized with keta-
mine (100 mg/kg) and xylazine (5 mg/kg) intramuscularly and were placed
supine on a thermoregulated surgical table. The penis was exposed by use of
a sterile technique. A 30-gauge insulin syringe was used to administer a single
injection of ad-LacZ (2 3 10
8 parts/20 mL) or ad–COMP-Ang1 (2 3 10
8 parts/20 mL)
and repeated injections of PBS (days 23 and 0; 20 mL) or COMP-Ang1 re-
combinant protein (days 23 and 0; 5.8 mg/20 mL) into the midportion of the
corpus cavernosum. The incision was closed with 6-O Vicryl (polyglactin 910)
sutures. We evaluated erectile function (n = 6 per group) by electrical stim-
ulation of the cavernous nerve 2 and 4 weeks after treatment. We administered
ad–COMP-Ang1 at a concentration of 2 3 10
8 parts because we could achieve
the highest erectile response at this concentration (J.-K. Ryu, W.J. Kim,
S. Piao, H.-R. Jin, and J.-K. Suh, unpublished observation). STZ-induced di-
abetic mice that received two successive intracavernous injections of COMP-
Ang1 protein showed signiﬁcant recovery of erectile function 2 and 4 weeks
after treatment, which was comparable to the function in the mice that received
a single intracavernous injection of ad–COMP-Ang1 (Fig. 1 and Supplementary
Fig. 2). On the basis of these functional results, the mice were divided into the
following four groups for histologic examination, biochemical study, and vas-
cular permeability testing: age-matched controls, STZ-induced diabetic mice
without treatment, STZ-induced diabetic mice receiving repeated intracavernous
injections of PBS (days 23 and 0; 20 mL), and STZ-induced diabetic mice re-
ceiving repeated intracavernous injections of COMP-Ang1 protein (days 23
and 0; 5.8 mg/20 mL). Fasting and postprandial blood glucose levels were de-
termined with an Accu-Check blood glucose meter (Roche Diagnostics,
Mannheim, Germany) before the mice were killed.
Physiological erection and inhibition studies. Erectile function was eval-
uated by electrical stimulation of the cavernous nerve. Stimulation parameters
were 1–5 V at a frequency of 12 Hz, a pulse width of 1 ms, and a duration of
1 min. The ratios of maximal intracavernous pressure (ICP) and total ICP (area
under the curve) to mean systolic blood pressure (MSBP) were calculated to
adjust for variations in systemic blood pressure, as previously described (12).
For inhibition studies, a separate group of STZ-induced diabetic mice was
given N-nitro-L-arginine methyl ester (L-NAME) (a NOS inhibitor, 75 mmol/L;
Sigma-Aldrich, St. Louis, MO) or apocynin (an inhibitor of NADPH oxidase
activation, 180 mmol/L; Sigma-Aldrich) in their drinking water beginning 1 day
before the intracavernous injection of the COMP-Ang1 protein.
Immunohistochemistry, in situ detection of superoxide anion, and the
terminal deoxynucleotidyl transferase dUTP nick-end labeling assay.
Immunohistochemistry, in situ detection of superoxide anion, and the terminal
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay were
performed as described in the Supplementary Methods.
Western blot and cGMP determination. Western blot for COMP-Ang1,
eNOS, phospho-eNOS, p47
phox, inducible NOS (iNOS), and endothelial cell-cell
junction proteins and cGMP determination were performed as described in the
Supplementary Methods.
Measurement of nitrite/nitrate (NOx) levels. Plasma NOx concentrations
were determined as described in the Supplementary Methods.
Measurement of permeability across the endothelium of cavernous
sinusoids. The mice from each STZ-induced diabetic group and their age-
matched controls were anesthetized, and the ﬂuorescent tracer rhodamine-
dextran (40 kDa, 25 mg/mL in saline; Molecular Probes, Eugene, OR) was
injected into the jugular vein. After 10 min, electrical stimulation of the cav-
ernous nerve was performed for 1 min to induce penile erection and to increase
blood ﬂow into the penis. Ten minutes after cavernous nerve stimulation,
corpus cavernosum tissues were harvested and ﬁxed in 4% paraformaldehyde
for 24 h at 4°C. Frozen tissue sections (n = 4 per group) were incubated with
antibody to platelet–endothelial cell adhesion molecule (PECAM)-1 (1:50;
Chemicon, Temecula, CA). The intensity of ﬂuorescence in the nonvascular area
of the corpus cavernosum tissue was measured by image analysis (NIH Image J).
Statistical analysis. Results are expressed as means 6 SE. Statistical analysis
was performed by using one-way ANOVA followed by Student-Newman-Keuls
post hoc tests. P , 0.05 was considered to be statistically signiﬁcant.
RESULTS
Metabolic variables. The fasting and postprandial blood
glucose concentrations of the STZ-induced diabetic mice
were signiﬁcantly higher than those of the control mice.
Body weight was signiﬁcantly lower in the STZ-induced
diabetic mice than in the controls. The body weight and
blood glucose levels of the STZ-induced diabetic mice did
not differ signiﬁcantly, regardless of the treatment given
(Table 1 and Supplementary Table 1).
In vivo COMP-Ang1 or b-gal expression in diabetic cor-
pus cavernosum tissue. Exogenous COMP-Ang1 protein
expression was detected by Western blot in the corpus
cavernosum tissue of STZ-induced diabetic mice 3, 7, 14,
and 21 days after injection of ad–COMP-Ang1. The level of
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days after injection, and expression still was detectable at
21 days (Supplementary Fig. 1A). We also evaluated the ex-
pression of COMP-Ang1 protein in the corpus cavernosum
at 1, 6, and 24 h and 3, 7, and 14 days after injection of
COMP-Ang1 recombinant protein. The level of COMP-Ang1
protein peaked at the earliest time point assayed (1 h) and
was detectable up to 3 days after injection (Supplementary
Fig. 1A).
To localize the COMP-Ang1 protein, either expressed
from ad–COMP-Ang1 or injected as a recombinant protein,
immunohistochemical staining for FLAG-tagged COMP-
Ang1 was performed 7 days after intracavernous injection
of ad-LacZ or ad–COMP-Ang1 and 1 h after intracavernous
injection of PBS or COMP-Ang1 protein.
The FLAG-tagged protein was strongly expressed in
endothelial cells in both the ad–COMP-Ang1– and COMP-
Ang1 protein–treated animals (Supplementary Fig. 1B).
FIG. 1. Adenoviral COMP-Ang1 gene or COMP-Ang1 protein transfer restores ICP elicited by electrical stimulation of the cavernous nerve.
A: Representative ICP responses for age-matched control mice (C), untreated STZ-induced diabetic mice (N), or STZ-induced diabetic mice
stimulated at 2 weeks after intracavernous injection of ad-LacZ (L; 2 3 10
8 parts/20 mL), PBS (P; 20 mL), ad–COMP-Ang1 (CA; 2 3 10
8 parts/
20 mL), or COMP-Ang1 protein (CP; 5.8 mg/20 mL). A single injection of ad-LacZ or ad–COMP-Ang1 (day 0) and repeated injections of PBS or
COMP-Ang1 protein (days 23 and 0) were done into the midportion of the corpus cavernosum. The cavernous nerve was stimulated at 1 and 5 V.
The stimulus interval is indicated by a solid bar. B and C: Ratios of mean maximal ICP and total ICP (area under the curve) to MSBP were cal-
culated for each group. Each bar depicts the means 6 SE from n = 6 animals per group. *P < 0.01 vs. the C, CA, and CP groups; #P < 0.01 vs. the
N, L, and P groups; †P < 0.01 vs. the C group; ‡P < 0.05 vs. the C group. DM, diabetes.
TABLE 1
Physiological and metabolic parameters: 2 weeks after treatment
Control
STZ-induced diabetic group
No treatment Ad-LacZ PBS Ad–COMP-Ang1 COMP-Ang1 protein
Body weight (g) 30.0 6 1.4 23.3 6 1.9* 22.9 6 1.3* 23.1 6 2.4* 22.4 6 1.2* 23.0 6 2.7*
Fasting glucose (mg/dL) 121.4 6 14.6 383.3 6 84.9* 413.4 6 66.8* 370.8 6 37.6* 377.8 6 62.3* 369.9 6 104.2*
Postprandial glucose (mg/dL) 171.9 6 14.7 498.1 6 23.7* 572.4 6 32.8* 565.4 6 24.4* 518.3 6 46.2* 459.9 6 71.9*
Blood pressure (mm Hg)
SBP 97.3 6 4.9 97.4 6 6.2 99.3 6 5.8 102.3 6 5.8 97.5 6 4.9 98.6 6 5.7
MBP 71.8 6 5.5 73.3 6 7.3 72.3 6 5.7 77.1 6 6.2 74.4 6 5.6 74.1 6 4.3
DBP 59.0 6 7.9 62.1 6 8.0 59.4 6 6.7 64.5 6 7.0 62.9 6 7.8 62.0 6 4.9
Data are means 6 SE for n = 6 animals per group. *P , 0.01 vs. control group.
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penis 7 days after injection of ad-LacZ showed uniform
staining along the penile shaft, whereas virtually no en-
dogenous b-gal activity was observed in animals injected
with the virus vehicle alone. Frozen transverse sections
from the penises of diabetic mice 7 days after injection of
ad-LacZ were used to determine its cellular distribution.
The X-gal staining was mainly observed in endothelial cells
lining the cavernous space (Supplementary Fig. 1C).
COMP-Ang1 gene or protein transfer restores erectile
function in STZ-induced diabetic mice. A representative
intracavernous tracing after stimulation of the cavernous
nerve (1–5 V, 12 Hz, 1 ms) for 1 min in age-matched control
or STZ-induced diabetic mice 2 and 4 weeks after treatment
is shown in Fig. 1A and Supplementary Fig. 2A,r e s p e c -
tively. During electrical stimulation of the cavernous nerve,
the ratios of maximal ICP and total ICP to MSBP were
signiﬁcantly lower in untreated STZ-induced diabetic mice
and STZ-induced diabetic mice treated with ad-LacZ or
PBS than in age-matched controls. A single intracavernous
injection of the ad–COMP-Ang1 gene or repeated intra-
cavernous injections of the COMP-Ang1 protein restored
erection parameters, which reached up to 83–89% of con-
trol values, and the physiological improvement lasted up to
4 weeks after treatment (Fig. 1B and C, and Supplementary
Fig. 2B and C). No detectable differences were found in
MSBP among the six experimental groups (Table 1 and
Supplementary Table 1). At 6 and 8 weeks after adminis-
tration of either the ad–COMP-Ang1 or COMP-Ang1 pro-
tein, however, erectile function returned to baseline levels
(Supplementary Fig. 3).
COMP-Ang1 protein transfer increases cavernous
endothelial content through enhanced endothelial
cell proliferation in STZ-induced diabetic mice. Im-
munohistochemical staining of cavernous tissue with an
antibody to PECAM-1 was performed in age-matched con-
trol and STZ-induced diabetic mice 2 weeks after treatment.
We found signiﬁcantly lower cavernous endothelial cell
content in the untreated and PBS-treated STZ-induced di-
abetic mice than in the control mice. Repeated intra-
cavernous injections of the COMP-Ang1 protein completely
restored cavernous endothelial content (Fig. 2A and C).
To test whether the COMP-Ang1 protein–induced in-
crease in cavernous endothelial content resulted from
endothelial cell proliferation, we assessed the number of
endothelial cells staining positive for phosphohistone H3
(a nuclear protein indicative of cell proliferation). Because
only a few or virtually no phosphohistone H3–positive
endothelial cells were noted in diabetic mice 2 weeks after
treatment with the COMP-Ang1 protein (data not shown),
we further investigated whether the COMP-Ang1 protein
induced endothelial cell proliferation at earlier time points.
We noted signiﬁcant increases in phosphohistone H3–
positive endothelial cells 1, 3, and 6 h after injection of the
COMP-Ang1 protein (Fig. 2B and D).
COMP-Ang1 protein transfer induces cavernous eNOS
phosphorylation and increases cGMP concentrations
in STZ-induced diabetic mice. Cavernous phospho-eNOS
(Ser1177) expression, as assessed by immunohistochemical
staining, was signiﬁcantly lower in the untreated and PBS-
treated STZ-induced diabetic mice than in the age-matched
controls at 2 weeks after treatment. Repeated intracavern-
ous injections of the COMP-Ang1 protein signiﬁcantly
increased endogenous eNOS phosphorylation in the STZ-
induced diabetic mice, which was comparable to that in
age-matched controls (Fig. 3A and B). Similar to the results
of immunohistochemical staining, immunoblot analysis of
the corpus cavernosum tissues revealed an increase in
cavernous phospho-eNOS expression in STZ-induced di-
abetic mice 2 weeks after treatment with the COMP-Ang1
protein, whereas no changes were noted in the total amount
of eNOS in control or STZ-induced diabetic mice regardless
of treatment (Fig. 3C).
Cavernous cGMP decreased signiﬁcantly in untreated
and PBS-treated STZ-induced diabetic mice compared with
that in the age-matched controls at 2 weeks after treatment.
Intracavernous administration of the COMP-Ang1 protein
signiﬁcantly increased cGMP concentrations compared with
those in untreated or PBS-treated STZ-induced diabetic mice
(Fig. 3D).
COMP-Ang1 protein transfer decreases cavernous
ROS production in STZ-induced diabetic mice. We
performed Western blots to evaluate the cavernous tissue
expression of p47
phox and iNOS in age-matched control
and STZ-induced diabetic mice 2 weeks after treatment.
Cavernous p47
phox and iNOS protein expression was sig-
niﬁcantly higher in the untreated and PBS-treated STZ-
induced diabetic mice than in the age-matched controls.
Repeated intracavernous injections of the COMP-Ang1 pro-
tein signiﬁcantly decreased cavernous p47
phox and iNOS
expression in the STZ-induced diabetic mice (Supplementary
Fig. 4).
In the in situ analysis of superoxide anion production, the
ﬂuorescent products of oxidized hydroethidine in both the
cavernous endothelium and the smooth muscle were signif-
icantly higher in the untreated and PBS-treated STZ-induced
diabetic groups than in the control group. Intracavernous
administration of the COMP-Ang1 protein signiﬁcantly de-
creased superoxide anion production in the cavernous en-
dothelial cells and smooth-muscle cells of STZ-induced
diabetic mice but not to the level found in the age-matched
controls (Fig. 4).
We also performed immunohistochemical localization of
nitrotyrosine to determine peroxynitrite generation, which
is derived from NO and superoxide anion. Nitrotyrosine
expression in endothelial cells and smooth-muscle cells of
the corpus cavernosum was higher in untreated and PBS-
treated STZ-induced diabetic groups than in the control
group. Repeated intracavernous injections of the COMP-
Ang1 protein signiﬁcantly decreased nitrotyrosine genera-
tion in the cavernous endothelial cells and smooth-muscle
cells of the STZ-induced diabetic mice, which was compa-
rable to that in age-matched controls (Fig. 5).
COMP-Ang1 protein transfer decreases apoptosis in
the cavernous endothelial cells and smooth-muscle
cells of STZ-induced diabetic mice. Double labeling of
cavernous tissue with TUNEL and the antibody to PECAM-1
or smooth-muscle a-actin showed that the number of apo-
ptotic cells in cavernous endothelial cells and smooth-
muscle cells was signiﬁcantly greater in the untreated and
PBS-treated STZ-induced diabetic groups than in the control
group. Repeated intracavernous injections of the COMP-
Ang1 protein signiﬁcantly decreased apoptosis in the cav-
ernous endothelial cells and smooth-muscle cells of the
STZ-induced diabetic mice, although not to the level found
in the age-matched controls (Fig. 6).
COMP-Ang1 protein transfer restores endothelial
cell-cell junction proteins and decreases cavernous
endothelial permeability in STZ-induced diabetic
mice. We performed Western blots to evaluate the cav-
ernous tissue expression of the adherens junction protein
(vascular endothelial [VE]-cadherin) and tight junction
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5) in age-matched control and STZ-induced diabetic mice
2 weeks after treatment. The cavernous expression of
VE-cadherin, ZO-1, occludin, and claudin-5 protein was
signiﬁcantly lower in the untreated and PBS-treated STZ-
induced diabetic mice than in the age-matched controls.
Repeated intracavernous injections of COMP-Ang1 protein
completely restored the expression of endothelial cell-cell
junction proteins in the diabetic mice (Fig. 7A–E).
Endothelial cell-cell junctions serve as a barrier by reg-
ulating paracellular permeability (30–33). Thus, we exam-
ined cavernous endothelial permeability in age-matched
control and STZ-induced diabetic mice 2 weeks after
treatment. We used 40 kDa rhodamine-dextran because we
found that signiﬁcant leakage of the 40-kDa ﬂuorescent
tracer occurred across the cavernous endothelium in STZ-
induced diabetic mice, whereas control mice showed min-
imal leakage (J.-K. Ryu, W.J. Kim, S. Piao, H.-R. Jin, and J.-K.
Suh, unpublished observation). We noted in a signiﬁcant
increase in rhodamine-dextran ﬂuorescence in the nonvas-
cular area of the corpus cavernosum tissue in untreated and
PBS-treated mice compared with that in control mice. Re-
peated intracavernous injections of COMP-Ang1 protein
signiﬁcantly decreased cavernous endothelial permeability
in the STZ-induced diabetic mice, which was similar to the
level found in age-matched controls (Fig. 7F and G).
FIG. 2. COMP-Ang1 protein transfer increases cavernous endothelial content through enhanced endothelial cell proliferation. A: Anti–PECAM-1
staining of cavernous tissue from age-matched control mice (C), untreated STZ-induced diabetic mice (N), or STZ-induced diabetic mice 2 weeks
after receiving repeated intracavernous injections of PBS (P; days 23 and 0; 20 mL) or COMP-Ang1 protein (CP; days 23 and 0; 5.8 mg/20 mL).
Scale bar = 100 mm. B: Immunohistochemical staining of cavernous tissue using antibodies to PECAM-1 (red) and phosphohistone H3 (PH3; green)
in untreated STZ-induced diabetic mice (0 h) or STZ-induced diabetic mice 1, 3, and 6 h after intracavernous injection of the COMP-Ang1 protein
(5.8 mg/20 mL). Scale bar = 50 mm. C: Quantitative analysis of endothelial cell content in the cavernous tissue was performed by using an image
analyzer. Each bar depicts the means 6 SE from n = 6 animals per group. *P < 0.01 vs. the C and CP groups; #P < 0.01 vs. the N and P groups.
D: Number of PH3-immunopositive endothelial cells per high-power ﬁeld (screen magniﬁcation 3400). Each bar depicts the means 6 SE from n =6
animals per group. #P < 0.01 vs. the 0-h group; ##P < 0.01 vs. the 1- and 6-h groups. DM, diabetes. (A high-quality color representation of this ﬁgure
is available in the online issue.)
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endothelial content and erectile function is NOS
dependent but not NADPH oxidase dependent. We
determined whether NOS or NADPH oxidase participated
in COMP-Ang1–induced cavernous angiogenesis and sub-
sequent restoration of the erectile response in L-NAME– or
apocynin-treated STZ-induced diabetic mice. Histologic and
physiological erection studies indicated that L-NAME–treated
FIG. 3. COMP-Ang1 protein transfer induces cavernous eNOS phosphorylation and increases cGMP concentration. A: Immunoﬂuorescent double
staining of cavernous tissue performed with antibodies to PECAM-1 (red) and phospho-eNOS (Ser1177; green) in age-matched control mice (C),
untreated STZ-induced diabetic mice (N), or STZ-induced diabetic mice 2 weeks after receiving intracavernous injections of PBS (P; days 23 and 0;
20 mL) or COMP-Ang1 protein (CP; days 23 and 0; 5.8 mg/20 mL). Scale bar = 100 mm. B: Quantitative analysis of phospho-eNOS–positive area in
the cavernous tissue was performed by using an image analyzer. Each bar depicts the means 6 SE from n = 6 animals per group. *P < 0.01 vs. the C
and CP groups; #P < 0.01 vs. the N and P groups. C: Western blot analysis demonstrating the relative abundance of phospho-eNOS (Ser1177) in
each group. Corpus cavernosum tissues were harvested after electrical stimulation of the cavernous nerve for 1 min. Results were similar for four
independent experiments. D: Cavernous cGMP concentrations. Each bar depicts the means 6 SE from n = 4 animals per group. *P < 0.01 vs. the
C and CP groups; #P < 0.01 vs. the N and P groups. DM, diabetes; P-eNOS, phosphorylated eNOS. (A high-quality color representation of this ﬁgure
is available in the online issue.)
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tein failed to restore cavernous endothelial content or re-
cover erectile function (Supplementary Fig. 5). In contrast,
treatment with apocynin did not block the COMP-Ang1
protein–induced enhancement of cavernous angiogenesis
and restoration of erectile function. Instead, a partial in-
crease in cavernous endothelial content or improvement
in erectile function was noted in the apocynin-treated
STZ-induced diabetic mice, but it did not reach the level of
the COMP-Ang1 treatment group. Apocynin signiﬁcantly
decreased superoxide anion production in the diabetic
corpus cavernosum tissue (Supplementary Fig. 5). We ob-
served a signiﬁcant reduction in plasma NOx levels in
L-NAME–treated diabetic animals (Supplementary Fig. 6).
The administration of L-NAME or apocynin did not inﬂuence
the body weight and blood glucose levels in the STZ-
induced diabetic mice (data not shown). These ﬁndings
suggest that the recovery of erectile function promoted by
COMP-Ang1–induced cavernous angiogenesis depends on
NOS but not on NADPH oxidase.
FIG. 4. COMP-Ang1 protein transfer decreases cavernous superoxide anion production. A: In situ detection of superoxide anion in endothelial cells
or smooth-muscle cells in age-matched control mice (C), untreated STZ-induced diabetic mice (N), or STZ-induced diabetic mice 2 weeks after
receiving intracavernous injections of PBS (P; days 23 and 0; 20 mL) or COMP-Ang1 protein (CP; days 23 and 0; 5.8 mg/20 mL). Corpus cavernosum
tissue was incubated with hydroethidine, an oxidative ﬂuorescent dye used to detect superoxide anion, and the antibody to PECAM-1 or with
hydroethidine and antibody to smooth-muscle a-actin. Scale bar = 50 mm. B and C: Number of ethidium bromide ﬂuorescence–positive endothelial
cells or smooth-muscle cells per high-power ﬁeld (screen magniﬁcation 3400). Each bar depicts the means 6 SE from n = 6 animals per group.
*P < 0.05 vs. the C and CP groups; #P < 0.05 vs. the N and P groups; †P < 0.05 vs. the C group. DM, diabetes. (A high-quality color representation of
this ﬁgure is available in the online issue.)
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We showed here that two successive injections of COMP-
Ang1 recombinant protein into the corpus cavernosum of
STZ-induced diabetic mice signiﬁcantly increased cavern-
ous endothelial cell proliferation, eNOS phosphorylation
(Ser1177), and cGMP expression and decreased the pro-
duction of ROS, such as superoxide anion and peroxynitrite.
These changes restored erectile function in STZ-induced
diabetic mice. Intracavernous injection of COMP-Ang1
protein also induced complete recovery of endothelial cell-
cell junction proteins and decreased cavernous endothelial
permeability in STZ-induced diabetic mice (Supplementary
Fig. 7).
To determine whether the improved erectile response
was related to an increase in the number of endothelial
cells, we assessed the expression of PECAM-1 by immu-
nohistochemical analysis. In agreement with the ﬁndings
of previous studies in STZ-induced diabetic rats (12,34,35),
we found a signiﬁcant decrease in the cavernous endo-
thelial area in untreated and PBS-treated STZ-induced
diabetic mice compared with that in control mice. COMP-
Ang1 protein induced complete recovery of the PECAM-
1–positive endothelial area in the corpus cavernosum.
Immunohistochemical examination of phosphohistone H3
expression revealed that the COMP-Ang1–induced in-
crease in cavernous endothelial content was the result of
endothelial proliferation, which is consistent with a recent
report (22).
In this study, COMP-Ang1 failed to induce cavernous an-
giogenesis and restore erectile function in L-NAME–treated
FIG. 5. COMP-Ang1 protein transfer decreases cavernous nitrotyrosine production. A: Immunoﬂuorescent double staining of cavernous tissue
performed with the antibody to nitrotyrosine, a marker of peroxynitrite formation, and the antibody to PECAM-1 or with antibodies to nitro-
tyrosine and smooth-muscle a-actin in age-matched control mice (C), untreated STZ-induced diabetic mice (N), or STZ-induced diabetic mice 2
weeks after receiving intracavernous injections of PBS (P; days 23 and 0; 20 mL) or COMP-Ang1 protein (CP; days 23 and 0; 5.8 mg/20 mL). Scale
bar = 100 mm. B and C: An image analyzer was used to quantitate nitrotyrosine-immunopositive endothelial or smooth-muscle area. Each bar
depicts the means 6 SE from n = 6 animals per group. *P < 0.05 vs. the C and CP groups; #P < 0.05 vs. the N and P groups. DM, diabetes. (A high-
quality color representation of this ﬁgure is available in the online issue.)
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tion mediated by COMP-Ang1–induced cavernous angio-
genesis depends on NOS, similar to results of a previous
study (36) showing that Ang1-induced angiogenesis was
abolished or reduced in the presence of the NOS inhibitor
L-NAME or in Nos3
2/2 mice. The NO/cGMP system is the
principal mediator of penile erection (37). In the current
study, eNOS phosphorylation (Ser1177) was signiﬁcantly
decreased in both untreated and PBS-treated STZ-induced
diabetic mice compared with the control group. A previous
study reported that eNOS is inactivated in the penis of STZ-
induced diabetic animals by O-linked N-acetylglucosamine
modiﬁcation, speciﬁcally at Ser1177 (38), and by increased
ROS generation (12). In the current study, endogenous
eNOS phosphorylation was completely restored in the STZ-
induced diabetic mice by the intracavernous injection of
FIG. 6. COMP-Ang1 protein transfer decreases apoptosis in cavernous endothelial cells and smooth-muscle cells. A: Double labeling of cavernous
tissue with TUNEL and the antibody to PECAM-1 or with TUNEL and the antibody to smooth-muscle a-actin in age-matched control mice (C),
untreated STZ-induced diabetic mice (N), or STZ-induced diabetic mice 2 weeks after receiving intracavernous injections of PBS (P; days 23 and 0;
20 mL) or COMP-Ang1 protein (CP; days 23 and 0; 5.8 mg/20 mL). Scale bar = 50 mm. B and C: Number of apoptotic cells in endothelial cells or
smooth-muscle cells per high-power ﬁeld (screen magniﬁcation 3400). Each bar depicts the means 6 SE from n = 6 animals per group. *P < 0.01 vs.
the C and CP groups; #P < 0.01 vs. the N and P groups; †P < 0.05 vs. the C group. DM, diabetes. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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resentative Western blot for VE-cadherin, ZO-1, occludin, and claudin-5 in age-matched control mice (C), untreated STZ-induced diabetic mice (N),
or STZ-induced diabetic mice 2 weeks after receiving intracavernous injections of PBS (P; days 23 and 0; 20 mL) or COMP-Ang1 protein (CP;
days 23 and 0; 5.8 mg/20 mL). B–E: Data are presented as the relative density of each protein compared with that of b-actin. The relative ratio of
the control group was arbitrarily set equivalent to 1. Data are representative of four independent experiments. *P < 0.05 vs. the C and CP groups;
#P < 0.05 vs. the N and P groups. F: Diffusion of ﬂuorescent tracer in the corpus cavernosum tissue. The ﬂuorescent tracer rhodamine-dextran
(red, 40 kDa; 25 mg/mL in saline) was injected into the jugular vein of each group of mice. After 10 min, corpus cavernosum tissues were harvested
after electrical stimulation of the cavernous nerve for 1 min to enhance blood ﬂow into the penis and were then stained with the antibody to
PECAM-1 (green). Scale bar = 50 mm. G: The intensity of ﬂuorescence in the nonvascular area of the corpus cavernosum tissue was measured
by image analysis. Each bar depicts the means 6 SE from n = 4 animals per group. *P < 0.01 vs. the C and CP groups; #P < 0.01 vs. the N and
P groups. DM, diabetes. (A high-quality color representation of this ﬁgure is available in the online issue.)
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thelial cells and a decrease in the generation of superoxide
anion and peroxynitrite in endothelial cells by COMP-Ang1
may account for the restoration of eNOS activity. Intra-
cavernous administration of COMP-Ang1 protein also sig-
niﬁcantly increased the concentration of cGMP, although
not to the level found in the age-matched controls. The in-
creased formation of cGMP resulting from recovery of NO
bioavailability is clear evidence of improved erectile re-
sponse to cavernous nerve stimulation in the diabetic mice.
The penises from STZ-induced diabetic mice had higher
superoxide anion and peroxynitrite levels than did those
from the controls. Endothelial cells generate ROS, which
plays a crucial role in physiological and pathological con-
ditions. Low levels of ROS function as signaling molecules
to mediate endothelial cell proliferation and migration in
response to hypoxia, ischemia, and angiogenic factors,
such as VEGF-A and Ang1 (39,40). A previous study (41) in
human umbilical vein endothelial cells reported that Ang1
triggers the production of superoxide anion by activating
NADPH oxidase and that this generation of superoxide
anions promotes endothelial cell migration. Furthermore,
endothelial NADPH oxidase–derived ROS plays a critical
role in Ang1-induced angiogenesis in porcine coronary
artery endothelial cells, and targeted deletion of the
NADPH oxidase subunit p47
phox gene suppresses Ang1-
induced angiogenesis (41), which suggests that ROS plays
an important role in promoting Ang1-mediated angiogen-
esis in physiological conditions. In contrast, high levels of
ROS in pathological conditions induce apoptosis and cell
death (42). In pathological conditions in which ROS is al-
ready generated at high levels, as in the current study,
COMP-Ang1 profoundly reduces the generation of super-
oxide anion and peroxynitrite in endothelial and smooth-
muscle cells, possibly by inhibiting the expression of
cavernous p47
phox and iNOS, respectively (Supplementary
Fig. 7). In agreement with these ﬁndings, intracavernous
administration of COMP-Ang1 protein signiﬁcantly reduced
the number of apoptotic cells in the cavernous endothelium
and smooth muscle in STZ-induced diabetic mice. In con-
trast to previous ﬁndings in physiological conditions in vitro
(41), inhibition of NADPH oxidase by apocynin did not
block COMP-Ang1–mediated cavernous angiogenesis in
STZ-induced diabetic mice in vivo. Instead, we observed
partial recovery of cavernous endothelial content and
erectile function in STZ-induced diabetic mice treated with
apocynin, although not to the level found in the COMP-
Ang1–treated group.
In the current study, cavernous endothelial permeability
to a 40-kDa ﬂuorescent tracer was increased in STZ-
induced diabetic mice concurrently with decreased ex-
pression of endothelial cell-cell junction proteins, including
VE-cadherin, ZO-1, occludin, and claudin-5. Similar to our
ﬁndings, several investigators (30–33,43,44) also reported
an increase in vascular permeability in STZ-induced di-
abetic retinal or cerebral microvasculature coincident with
a decrease in endothelial junction proteins. These ﬁndings
suggest that alterations in endothelial junction proteins in
diabetes may be a mechanism by which cavernous endo-
thelial permeability is increased. Intracavernous injection
of the COMP-Ang1 protein signiﬁcantly decreased cav-
ernous endothelial permeability in STZ-induced diabetic
mice by restoring endothelial cell-cell junction proteins.
Speciﬁc activation of Tie2 in cell-cell contact in the qui-
escent vasculature also is known to be a mechanism by
which Ang1 reduces endothelial permeability and promotes
vessel stabilization (29).
Because of concerns about the utility of viral vector–
mediated gene therapy for non–life-threatening disease,
such as erectile dysfunction, it is necessary to evaluate
whether an angiogenic factor can restore erectile function
when it is given as a recombinant protein. Compared with
that in STZ-induced diabetic animals that received a single
intracavernous injection of ad–COMP-Ang1, the similar
restoration of erectile function after two successive injec-
tions of COMP-Ang1 protein is noteworthy. From a clinical
standpoint, therapeutic proteins are safer and more feasible
for treating humans than is gene therapy.
In summary, intracavernous delivery of the recombinant
COMP-Ang1 protein successfully restored the endogenous
NO-cGMP pathway through the regeneration of healthy
and nonleaky cavernous endothelium and inhibition of
ROS-mediated cavernous endothelial cell apoptosis. Fur-
thermore, these changes resulted in physiologically rele-
vant changes in erectile function. These ﬁndings support
the concept of angiogenic factor therapy as a curative
therapy for erectile dysfunction. Cavernous endothelial
regeneration by use of angiogenic factor protein is a novel
therapeutic strategy for treating erectile dysfunction
resulting from diabetes.
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